The Proof with Simon Hill
The Proof with Simon Hill

The Peptides Quietly Accelerating Aging | Dr Valter Longo

May 11, 2026

AI Summary

5 min read

Dr. Valter Longo has spent over 30 years studying the biology of aging, and his message about the peptide craze is direct: the growth hormone secretagogues being sold online to people in their 30s and 40s are likely accelerating the very aging process they claim to slow. These unregulated compounds, which tell the body to produce more growth hormone, activate pathways that decades of research—from yeast to mice to human genetics—consistently link to shorter lifespan and more disease. The episode is a deep dive into why that is, what the long-term data actually shows, and what people can do instead with nutrition to shift their cells into a protective, repair-oriented state.

The GLP-1 Precedent and the Problem with "Better Than Nothing"

Longo uses the GLP-1 receptor agonist craze as a cautionary parallel. While these drugs produce dramatic short-term weight loss, the long-term picture is less rosy. He cites data showing that 92% of people quit within three years, and upon stopping, weight is regained quickly—often faster than if lost through diet alone—because the body's natural GLP-1 production may be suppressed. The net result over several years, he estimates, might be a loss of only a few kilograms of fat alongside a significant loss of lean body mass, including muscle and bone.

Continue reading the full summary in the app — free to try.

Read Full Summary →

Free • No credit card required

Listen to Audio Summary Open in App

What you'll learn

  • 1 (00:00) **Peptides, Aging, and the Growth Hormone Trap** - Simon Hill introduces the peptide craze and frames the conversation around Dr. Valter Longo's three decades of research on the biology these compounds activate.
  • 2 (02:40) **GLP-1s: Short-Term Wins, Long-Term Risks** - Longo critiques the "better than nothing" logic for GLP-1s, comparing the 10% mortality reduction from drugs to the 25% reduction from a Mediterranean diet.
  • 3 (09:10) **The Problem with "Next-Gen" GLP-1s** - Longo explains why stacking drugs to fix side effects of the first drug is a flawed approach, using a car analogy.
  • 4 (14:03) **Growth Hormone Secretagogues: The Opposite of Longevity** - Longo explains how secretagogues (e.g., tesamorelin, CJC-1295) mimic growth hormone releasing hormone, raising IGF-1.
  • 5 (20:31) **The Short-Term Muscle vs. Long-Term Disease Trade-Off** - Longo acknowledges that these peptides build muscle in the short term, but warns of long-term consequences.
  • 6 (26:27) **Human Genetics: The Ecuador Study** - Longo presents evidence from a population in Ecuador with Laron syndrome (growth hormone receptor deficiency).
  • 7 (33:48) **The Analogy of the Old Car Engine** - Longo argues that replacing declining growth hormone in old age is like putting a powerful new engine in an old car—it will likely break down.

+ Full timestamped outline available in the app

Show Notes

The peptide and GLP-1 conversation has reached a fever pitch. Growth-hormone-releasing peptides are being marketed as longevity tools, GLP-1s are being treated as a default rather than a last resort, and a wellness aesthetic of higher IGF-1, more muscle, and less fat is being sold as the route to a longer life. In this episode, I sit down with Dr Valter Longo, Professor of Gerontology at USC and Director of the USC Longevity Institute, to look at what the data actually says.

Valter developed the Fasting-Mimicking Diet, has led foundational work on the growth hormone, IGF-1, insulin, and TOR axis across yeast, mice, and humans, and runs non-profit longevity foundation clinics in Europe and the US. He calls himself the anti-biohacker and makes the case using the totality of evidence rather than the loudest claim.

What we cover:

  • The peptide boom and why every line of evidence cuts the other way
  • The body composition reality of GLP-1s after 3 to 4 years
  • The optimal IGF-1 range and how to land there with food and timing
  • The Fasting-Mimicking Diet across more than 47 clinical trials, including the biological-age reduction studies
  • The Harvard plant-versus-animal protein data, properly read
  • A grounded case against ketogenic patterns for longevity and what to eat instead

If this conversation lands, a quick rating or review on Apple Podcasts or Spotify makes a real difference.

To follow more of Dr Valter Longo's work, visit his website, find him on Instagram, and explore the work of the Create Cures Foundation, the Valter Longo Foundation, the Longevity Technology Institute, and the European Longevity Institute through his published research and his book The Longevity Diet.

  • Intro (00:00)
  • The Peptide Boom and What Is Actually Being Sold (00:01)
  • GLP-1s: 92 Per Cent Drop-Out and the Body Composition Math (00:02)
  • The Fasting-Mimicking Diet Reverses Western-Diet Damage (00:13)
  • Snell, Ames, and Laron Dwarf Mice (00:18)
  • The Laron Syndrome Cohort in Ecuador (00:24)
  • Acromegaly and the Cost of High Growth Hormone (00:28)
  • The Optimal IGF-1 Range: 120 to 160 ng/mL (00:50)
  • Plant vs Animal Protein, Properly Read (00:57)
  • The Anti-Keto Case from Okinawa to Loma Linda (01:08)
  • Stanford Crohn's, Miami UC, and Rome Kidney Disease (01:22)
  • Biological Age Reduction After Three FMD Cycles (01:25)
  • FMD Safety Across More Than a Million Users (01:31)
  • The Longevity Diet: Eat More, Eat Better (01:43)

This episode is brought to you by:

The Proof with Simon Hill

More from this podcast

The Proof with Simon Hill →